Biology subjects

Marbach, D.

Publications and source records attributed to Marbach, D..

8 recordsLinked to original sources

bioRxiv2024

Comparison of Fixed Single Cell RNA-seq Methods to Enable Transcriptome Profiling of Neutrophils in Clinical Samples

Monitoring neutrophil gene expression is a powerful tool for understanding disease mechanisms, developing new diagnostics, therapies and optimizing clinical trials. Neutrophils are sensitive to the processing, storage and transportation steps that are involved in clinical sample analysis. This study is the first to evaluate the capabilities of technologies from 10X Genomics, PARSE Biosciences, and HIVE (Honeycomb Biotechnologies) to generate high-quality RNA data from human blood-derived neutrophils. Our comparative analysis shows that all methods produced high quality data, importantly capturing the transcriptomes of neutrophils. 10X FLEX cell populations in particular showed a close concordance with the flow cytometry data. Here, we establish a reliable single-cell RNA sequencing workflow for neutrophils in clinical trials: we offer guidelines on sample collection to preserve RNA quality and demonstrate how each method performs in capturing sensitive cell populations in clinical practice.

genomics↗

bioRxiv2023

Contextualizing protein representations using deep learning on protein networks and single-cell data

Understanding protein function and developing molecular therapies require deciphering the cell types in which proteins act as well as the interactions between proteins. However, modeling protein interactions across biological contexts remains challenging for existing algorithms. Here, we introduce PO_SCPLOWINNACLEC_SCPLOW, a geometric deep learning approach that generates context-aware protein representations. Leveraging a multi-organ single-cell atlas, PO_SCPLOWINNACLEC_SCPLOW learns on contextualized protein interaction networks to produce 394,760 protein representations from 156 cell type contexts across 24 tissues. PO_SCPLOWINNACLEC_SCPLOWs embedding space reflects cellular and tissue organization, enabling zero-shot retrieval of the tissue hierarchy. Pretrained protein representations can be adapted for downstream tasks: enhancing 3D structure-based representations for resolving immuno-oncological protein interactions, and investigating drugs effects across cell types. PO_SCPLOWINNACLEC_SCPLOW outperforms state-of-the-art models in nominating therapeutic targets for rheumatoid arthritis and inflammatory bowel diseases, and pinpoints cell type contexts with higher predictive capability than context-free models. PO_SCPLOWINNACLEC_SCPLOWs ability to adjust its outputs based on the context in which it operates paves way for large-scale context-specific predictions in biology.

bioinformatics↗

bioRxiv2021

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

Targeting chromatin binding proteins and modifying enzymes can concomitantly affect tumor cell proliferation and survival, as well as enhance anti-tumor immunity and augment cancer immunotherapies. By screening a small molecule library of epigenetics-based therapeutics, BET bromodomain inhibitors (BETi) were identified as agents that promote the anti-tumor activity of CD8+ T-cells. BETi sensitized diverse tumor types to the cytotoxic effects of the pro-inflammatory cytokine TNF. By preventing the recruitment of BRD4 to p65-bound cis-regulatory elements, BETi suppressed the induction of inflammatory gene expression, including the key NF-{kappa}B target genes BIRC2 (cIAP1) and BIRC3 (cIAP2). Disruption of pro-survival NF-{kappa}B signaling by BETi led to unrestrained TNF-mediated activation of the extrinsic apoptotic cascade and tumor cell death. Administration of BETi in combination with T-cell bispecific (TCB) antibodies increased bystander killing of tumor cells and enhanced tumor growth inhibition in vivo in a TNF-dependent manner. This novel epigenetic mechanism of immunomodulation may guide future use of BETi as adjuvants for immune oncology agents. STATEMENT OF SIGNIFICANCEManipulating the epigenome is an evolving strategy to enhance anti-tumor immunity. We demonstrate that BET bromodomain inhibitors potently sensitize solid tumors to CD8+ T-cell killing in a TNF-dependent manner. This immunomodulatory mechanism can be therapeutically leveraged to augment immuno-oncology therapies, including TCB antibodies and immune checkpoint blockade.

cancer biology↗

bioRxiv2019

Gene-set enrichment with regularized regression

MotivationCanonical methods for gene-set enrichment analysis assume independence between gene-sets. In practice, heterogeneous gene-sets from diverse sources are frequently combined and used, resulting in gene-sets with overlapping genes. They compromise statistical modelling and complicate interpretation of results.\n\nResultsWe rephrase gene-set enrichment as a regression problem. Given some genes of interest (e.g. a list of hits from an experiment) and gene-sets (e.g. functional annotations or pathways), we aim to identify a sparse list of gene-sets for the genes of interest. In a regression framework, this amounts to identifying a minimum set of gene-sets that optimally predicts whether any gene belongs to the given genes of interest. To accommodate redundancy between gene-sets, we propose regularized regression techniques such as the elastic net. We report that regression-based results are consistent with established gene-set enrichment methods but more parsimonious and interpretable.\n\nAvailabilityWe implement the model in gerr (gene-set enrichment with regularized regression), an R package freely available at https://github.com/TaoDFang/gerr and submitted to Bioconductor. Code and data required to reproduce the results of this study are available at https://github.com/TaoDFang/GeneModuleAnnotationPaper.\n\nContactJitao David Zhang (jitao_david.zhang@roche.com), Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel, Switzerland.

bioinformatics↗

bioRxiv2019

DreamDMI: a tool for Disease Module Identification in molecular networks

SummaryWe define a disease module as a partition of a molecular network whose components are jointly associated with one or several diseases or risk factors thereof. Identification of such modules, across different types of networks, has great potential for elucidating disease mechanisms and establishing new powerful bio-markers. To this end, we launched the \"Disease Module Identification (DMI) DREAM Challenge\", a community effort to build and evaluate unsupervised molecular network modularisation algorithms (Choobdar et al., 2018). Here we present MONET, a toolbox providing easy and unified access to the three top methods from the DMI DREAM Challenge for the bioinformatics community.\n\nAvailability and ImplementationMONET is a command line tool for Linux, based on Docker and Singularity containers; the core algorithms were written in R, Python, Ada and C++. It is freely available for download at https://github.com/BergmannLab/MONET.git\n\nContactmattia.tomasoni@unil.ch (MT); sven.bergmann@unil.ch (SB)

bioinformatics↗

bioRxiv2018

Predicting trait regulators by identifying co-localization of DNA binding and GWAS variants in regulatory regions

Genomic regions associated with complex traits and diseases are primarily located in non-coding regions of the genome and have unknown mechanism of action. A critical step to understanding the genetics of complex traits is to fine-map each associated locus; that is, to find the causal variant(s) that underlie genetic associations with a trait. Fine-mapping approaches are currently focused on identifying genomic annotations, such as transcription factor binding sites, which are enriched in direct overlap with candidate causal variants. We introduce CONVERGE, the first computational tool to search for co-localization of GWAS causal variants with transcription factor binding sites in the same regulatory regions, without requiring direct overlap. As a proof of principle, we demonstrate that CONVERGE is able to identify five novel regulators of type 2 diabetes which subsequently validated in knockdown experiments in pancreatic beta cells, while existing fine-mapping methods were unable to find any statistically significant regulators. CONVERGE also recovers more established regulators for total cholesterol compared to other fine-mapping methods. CONVERGE is therefore unique and complementary to existing fine-mapping methods and is useful for exploring the regulatory architecture of complex traits.

bioinformatics↗

bioRxiv2018

Open Community Challenge Reveals Molecular Network Modules with Key Roles in Diseases

Identification of modules in molecular networks is at the core of many current analysis methods in biomedical research. However, how well different approaches identify disease-relevant modules in different types of gene and protein networks remains poorly understood. We launched the "Disease Module Identification DREAM Challenge", an open competition to comprehensively assess module identification methods across diverse protein-protein interaction, signaling, gene co-expression, homology, and cancer-gene networks. Predicted network modules were tested for association with complex traits and diseases using a unique collection of 180 genome-wide association studies (GWAS). Our critical assessment of 75 contributed module identification methods reveals novel top-performing algorithms, which recover complementary trait-associated modules. We find that most of these modules correspond to core disease-relevant pathways, which often comprise therapeutic targets and correctly prioritize candidate disease genes. This community challenge establishes benchmarks, tools and guidelines for molecular network analysis to study human disease biology (https://synapse.org/modulechallenge).

bioinformatics↗

bioRxiv2017

Intra- and inter-chromosomal chromatin interactions mediate genetic effects on regulatory networks

Genome-wide studies on the genetic basis of gene expression and the structural properties of chromatin have considerably advanced our understanding of the function of the human genome. However, it remains unclear how structure relates to function and, in this work, we aim at bridging both by assembling a dataset that combines the activity of regulatory elements (e.g. enhancers and promoters), expression of genes and genetic variations of 317 individuals and across two cell types. We show that the regulatory activity is structured within 12,583 Cis Regulatory Domains (CRDs) that are cell type specific and highly reflective of the local (i.e. Topologically Associating Domains) and global (i.e. A/B nuclear compartments) nuclear organization of the chromatin. These CRDs essentially delimit the sets of active regulatory elements involved in the transcription of most genes, thereby capturing complex regulatory networks in which the effects of regulatory variants are propagated and combined to finally mediate expression Quantitative Trait Loci. Overall, our analysis reveals the complexity and specificity of cis and trans regulatory networks and their perturbation by genetic variation.

genomics↗